Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

A modeling analysis of the effects of molecular size and binding affinity on tumor targeting.

Schmidt MM, Wittrup KD.

Mol Cancer Ther. 2009 Oct;8(10):2861-71. doi: 10.1158/1535-7163.MCT-09-0195.

2.

Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors.

Sung C, Shockley TR, Morrison PF, Dvorak HF, Yarmush ML, Dedrick RL.

Cancer Res. 1992 Jan 15;52(2):377-84.

3.

Influence of the duration of intravenous drug administration on tumor uptake.

Fouliard S, Chenel M, Marcucci F.

Front Oncol. 2013 Jul 25;3:192. doi: 10.3389/fonc.2013.00192. eCollection 2013.

4.

Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size.

Zahnd C, Kawe M, Stumpp MT, de Pasquale C, Tamaskovic R, Nagy-Davidescu G, Dreier B, Schibli R, Binz HK, Waibel R, Plückthun A.

Cancer Res. 2010 Feb 15;70(4):1595-605. doi: 10.1158/0008-5472.CAN-09-2724. Epub 2010 Feb 2.

5.

Practical theoretic guidance for the design of tumor-targeting agents.

Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ.

Methods Enzymol. 2012;503:255-68. doi: 10.1016/B978-0-12-396962-0.00010-0.

6.

A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density.

Gray BP, McGuire MJ, Brown KC.

PLoS One. 2013 Aug 23;8(8):e72938. doi: 10.1371/journal.pone.0072938. eCollection 2013.

7.
8.

Tumor targeting efficiency of bare nanoparticles does not mean the efficacy of loaded anticancer drugs: importance of radionuclide imaging for optimization of highly selective tumor targeting polymeric nanoparticles with or without drug.

Lee BS, Park K, Park S, Kim GC, Kim HJ, Lee S, Kil H, Oh SJ, Chi D, Kim K, Choi K, Kwon IC, Kim SY.

J Control Release. 2010 Oct 15;147(2):253-60. doi: 10.1016/j.jconrel.2010.07.096. Epub 2010 Jul 16.

PMID:
20624433
9.

Side-by-Side Comparison of Commonly Used Biomolecules That Differ in Size and Affinity on Tumor Uptake and Internalization.

Leelawattanachai J, Kwon KW, Michael P, Ting R, Kim JY, Jin MM.

PLoS One. 2015 Apr 22;10(4):e0124440. doi: 10.1371/journal.pone.0124440. eCollection 2015.

10.

A mechanistic compartmental model for total antibody uptake in tumors.

Thurber GM, Dane Wittrup K.

J Theor Biol. 2012 Dec 7;314:57-68. doi: 10.1016/j.jtbi.2012.08.034. Epub 2012 Sep 6.

11.

Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles.

Rangger C, Helbok A, von Guggenberg E, Sosabowski J, Radolf T, Prassl R, Andreae F, Thurner GC, Haubner R, Decristoforo C.

Int J Nanomedicine. 2012;7:5889-900. doi: 10.2147/IJN.S36847. Epub 2012 Nov 27.

12.

Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition.

Tolmachev V, Tran TA, Rosik D, Sjöberg A, Abrahmsén L, Orlova A.

J Nucl Med. 2012 Jun;53(6):953-60. doi: 10.2967/jnumed.111.101527. Epub 2012 May 14.

13.

Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles.

Rangger C, Helbok A, Sosabowski J, Kremser C, Koehler G, Prassl R, Andreae F, Virgolini IJ, von Guggenberg E, Decristoforo C.

Int J Nanomedicine. 2013;8:4659-71. doi: 10.2147/IJN.S51927. Epub 2013 Dec 5.

14.
15.

Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.

Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, Bading JR, Laug WE, Conti PS.

J Nucl Med. 2004 Oct;45(10):1776-83.

16.

Effect of small-molecule-binding affinity on tumor uptake in vivo: a systematic study using a pretargeted bispecific antibody.

Orcutt KD, Rhoden JJ, Ruiz-Yi B, Frangioni JV, Wittrup KD.

Mol Cancer Ther. 2012 Jun;11(6):1365-72. doi: 10.1158/1535-7163.MCT-11-0764. Epub 2012 Apr 5.

17.

In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size.

Fang C, Shi B, Pei YY, Hong MH, Wu J, Chen HZ.

Eur J Pharm Sci. 2006 Jan;27(1):27-36. Epub 2005 Sep 16.

PMID:
16150582
18.

Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.

Jain R, Rawat A, Verma B, Markiewski MM, Weidanz JA.

J Natl Cancer Inst. 2013 Feb 6;105(3):202-18. doi: 10.1093/jnci/djs521. Epub 2013 Jan 8.

19.

In vivo tumor targeting of gold nanoparticles: effect of particle type and dosing strategy.

Puvanakrishnan P, Park J, Chatterjee D, Krishnan S, Tunnell JW.

Int J Nanomedicine. 2012;7:1251-8. doi: 10.2147/IJN.S29147. Epub 2012 Mar 6.

20.

Ultrasound exposure improves the targeted therapy effects of galactosylated docetaxel nanoparticles on hepatocellular carcinoma xenografts.

Wei H, Huang J, Yang J, Zhang X, Lin L, Xue E, Chen Z.

PLoS One. 2013;8(3):e58133. doi: 10.1371/journal.pone.0058133. Epub 2013 Mar 1.

Items per page

Supplemental Content

Write to the Help Desk